Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1981 Jan;34(1):54–57. doi: 10.1136/jcp.34.1.54

Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.

P J Heyburn, J A Child, M Peacock
PMCID: PMC1146409  PMID: 6450779

Abstract

In order to define the relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis 22 untreated patients were studied, of whom 12 were hypercalcaemic. Most patients had malabsorption of radiocalcium from the gastrointestinal tract and evidence of increased bone resorption as assessed by fasting urinary hydroxyproline/creatinine ratio. The mean OHPr/Cr ratio, however, was similar in patients with and without hypercalcaemia. Renal failure and Bence Jones proteinuria occurred more frequently in the hypercalcaemic patients. In four patients with hypercalcaemia there was an increase in OHPr/Cr after saline infusion accompanied by an improvement in renal function and hypercalcaemia. Mithramycin given to the same patients further reduced hypercalcaemia, presumably by inhibiting bone resorption. It was concluded that the hypercalcaemia of myelomatosis is due to the combination of renal failure and increased bone resorption, but that the OHPr/Cr ratio in the untreated state is a poor indicator of the degree of bone resorption in hypercalcaemic patients.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Balcerzak S., Bonnet J. D., Gehan E. A., Haut A., Hewlett J. S., Monto R. W. Prognostic factors in multiple myeloma. Cancer. 1975 Oct;36(4):1192–1201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  2. BENTZEL C. J., CARBONE P. P., ROSENBERG L. THE EFFECT OF PREDNISONE ON CALCIUM METABOLISM AND CA47 KINETICS IN PATIENTS WITH MULTIPLE MYELOMA AND HYPERCALCEMIA. J Clin Invest. 1964 Nov;43:2132–2145. doi: 10.1172/JCI105087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Condon J. R., Reith S. B., Nassim J. R., Millard F. J., Hilb A., Stainthorpe E. M. Treatment of Paget's disease of bone with mithramycin. Br Med J. 1971 Feb 20;1(5746):421–423. doi: 10.1136/bmj.1.5746.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DeFronzo R. A., Cooke C. R., Wright J. R., Humphrey R. L. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978 Mar;57(2):151–166. doi: 10.1097/00005792-197803000-00003. [DOI] [PubMed] [Google Scholar]
  5. Filastre J. P., Humbert G., Leroy J., Maitrot J., Deshayes P., Canonne M. A. Furosemide, mithramycin, and salmon calcitonin in hypercalcemia. Eur J Intensive Care Med. 1975 Dec;1(4):185–188. doi: 10.1007/BF00624436. [DOI] [PubMed] [Google Scholar]
  6. Garnick M. B., Mayer R. J. Acute renal failure associated with neoplastic disease and its treatment. Semin Oncol. 1978 Jun;5(2):155–165. [PubMed] [Google Scholar]
  7. Godfrey T. E. Mithramycin for hypercalcemia of malignant disease. Calif Med. 1971 Oct;115(4):1–4. [PMC free article] [PubMed] [Google Scholar]
  8. Hobbs J. R. Paraproteins, benign or malignant? Br Med J. 1967 Sep 16;3(5567):699–704. doi: 10.1136/bmj.3.5567.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hodkinson H. M. Serum calcium in a geriatric inpatient population. Age Ageing. 1973 Aug;2(3):157–162. doi: 10.1093/ageing/2.3.157. [DOI] [PubMed] [Google Scholar]
  10. Kiang D. T., Loken M. K., Kennedy B. J. Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab. 1979 Feb;48(2):341–344. doi: 10.1210/jcem-48-2-341. [DOI] [PubMed] [Google Scholar]
  11. Kohn J., Riches P. G. A cellulose acetate immunofixation technique. J Immunol Methods. 1978;20:325–331. doi: 10.1016/0022-1759(78)90268-5. [DOI] [PubMed] [Google Scholar]
  12. LAZOR M. Z., ROSENBERG L., CARBONE P. STUDIES OF CALCIUM METABOLISM IN MULTIPLE MYELOMA WITH CALCIUM AND METABOLIC-BALANCE TECHNIQUES. J Clin Invest. 1963 Aug;42:1238–1247. doi: 10.1172/JCI104809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. OSSERMAN E. F., TAKATSUKI K. PLASMA CELL MYELOMA: GAMMA GLOBULIN SYNTHESIS AND STRUCTURE. A REVIEW OF BIOCHEMICAL AND CLINICAL DATA, WITH THE DESCRIPTION OF A NEWLY-RECOGNIZED AND RELATED SYNDROME, "H-GAMMA-2-CHAIN (FRANKLIN'S) DISEASE. Medicine (Baltimore) 1963 Nov;42:357–384. [PubMed] [Google Scholar]
  14. Stamp T. C., Child J. A., Walker P. G. Treatment of osteolytic myelomatosis with mithramycin. Lancet. 1975 Mar 29;1(7909):719–722. doi: 10.1016/s0140-6736(75)91631-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES